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Despite the low incidence, diagnostic and therapeutic advances, hypopharyngeal cancer still 
has high mortality.
Objective: To evaluate retrospectively the epidemiological profile and response to surgery and 
radiation/chemotherapy of patients with hypopharyngeal cancer.
Method: We reviewed the medical records of 114 patients treated between 2002 and 2009 in a 
tertiary hospital with histopathological diagnosis of squamous cell carcinoma.
Results: The mean age of the patients was 57 years, 94.7% were males and 5.3% females, 98.2% were 
smokers and 92% consumed alcohol; 72% are illiterate or did not complete first grade schooling. 
The main complaints were: neck node (28%), pain and dysphagia (22%), odynophagia (12.2%), 
dysphonia (7.8%). The clinical staging was: I (1.7%), II (3.5%), III (18.4%), IV (76.3%). The treatment 
was carried out with radiotherapy and chemotherapy alone in 35%, with mean 2-year survival of 20% 
and 5-year survival of 18%; surgery followed by radiotherapy and chemotherapy in 22.8% with 2-year 
survival of 60.0% and 5 years of 55.0%; chemotherapy alone in 2.6%, and 39.4% without treatment.
Conclusion: Most patients already had advanced clinical stages and independent of the treatment 
option, had a low survival rate, confirming the poor prognosis of this neoplasm.
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INTRODUCTION
Squamous cell carcinoma of the hypopharynx 
is relatively rare and bears the worst prognosis of all 
head and neck tumors, particularly those located in the 
piriform recess which is the most frequent site of origin 
in the hypopharynx1,2. According to U.S. data from the 
National Cancer Data Base, this condition corresponds 
to 4% of all head and neck tumors and 7% of all malig-
nancies of the upper aerodigestive tract3. According to 
national data from the Brazilian INCA, it accounts for 
30% of pharyngeal tumors, it predominates in males and 
80% are located in the piriform recess4. Among the major 
risk factors we list smoking and alcohol consumption, 
which separately have specific and significant effects in 
the hypopharynx, besides having a statistically signifi-
cant synergistic effect according to numerous authors5; 
and as for complementary risk factors we have sidero-
penia and syphilis4.
There is a high incidence of advanced cases already 
found upon initial presentation compared to other sites 
of the head and neck, such as the larynx6, having distant 
metastases, and especially regional metastases - which may 
be the first clinical manifestation of the disease7. Data from 
the Department of Health shows that 23% of patients are in 
clinical stage III and 72% in stage IV4 - which causes these 
patients to have a median five-year survival by disease 
stage of 56% and 32%, respectively4.
There are many reasons for this poor prognosis: the 
hypopharynx is a silent area, patients usually have a bad 
overall clinical and nutritional status, submucosal spread 
is characteristic in these cases with known likelihood of 
developing regional and distant metastases, and capacity 
for direct invasion of adjacent organs of the head and 
neck8. Treatment decision is impaired because of the 
aforementioned prognosis, low nutritional intake upon 
admission and the high occurrence of second primary 
tumors, which together lead to a considerable reduction 
in overall survival9.
In our clinic, the standard treatment is carried out 
by partial surgery or radiation therapy for T1 and T2 cases, 
and pharyngolaryngectomy for T3 and T4 cases with a 
reserved preservation protocol for cases with a functional 
larynx. Because of disease-inherent factors and its carrier, 
and the aforementioned therapeutic weapons available, 
decisions are mainly based on: administering more or less 
powerful chemotherapeutic agents; carry on extended field 
or narrow field radiotherapy, and perform an extensive 
surgical resection, followed by the necessary reconstruc-
tion or a less extensive resection10.
Still talking about treatment, it should be noted that 
despite the availability of more potent chemotherapeutic 
agents in the market, more targeted radiotherapy 
modalities, improvements in surgical techniques, and 
especially the possibilities of reconstruction, more 
accurate imaging and better understanding of the 
pathophysiology of this disease10, we could not trans-
late these advances into improved overall survival, 
confirming the difficulty in selecting the best treatment 
for each case.
The objective of this study is to evaluate the epi-
demiology of the patients admitted to a tertiary hospital 
with a diagnosis of squamous cell carcinoma of the 
hypopharynx, its relationship with the risk factors, as 
well as an analysis of survival according to treatment.
METHOD
This is a retrospective study of patients with squa-
mous cell carcinoma of the hypopharynx treated between 
2001 and 2009 in a tertiary hospital with histopathologi-
cal confirmation, and we took off tumors of other sites 
extending to the hypopharynx, as well as suspicious 
lesions and second tumors in this region without patho-
logic confirmation.
This study was approved by the Ethics Committee 
of the Institution where it was performed under protocol 
No. 71/2000.
RESULTS
We selected 114 patients with squamous cell car-
cinoma of the hypopharynx. The patients’ ages ranged 
from 38 to 81 years, with mean age of 57 years, occurring 
predominantly in males, with 108 men (94.7%) and only 
eight women (5.3%) in our sample.
The chief complaint at presentation was a cervical 
node in 28% of cases, followed by pain and dysphagia 
(22%), sore throat (12.2%), dysphonia (7.8%) and foreign 
body sensation (6.1%) and there may be an initial mani-
festation of more than one concomitant symptom. The 
mean time between the onset of the chief complaint and 
admission to the clinic was 5.4 months (ranging between 
1 and 24 months).
Regarding the clinical stage at initial presentation: 
1.7% was in stage I; 3.5% in stage II; 18.4% stage III; and 
76.3% were in stage IV. Among the major risk factors, we 
found that 98.2% were smokers and 92% were alcoholics. 
With respect to educational level, 72% were illiterate or 
had incomplete basic education.
Regarding treatment, surgery was the initial choice 
in 26 patients (22.8%) followed by radiotherapy. The 
disease-free and overall survival curves of this group were 
traced using the Kaplan-Meier method and are presented 
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DISCUSSION
This was a retrospective study carried out in one 
single institution, which evaluated patients with confir-
med diagnosis of epidermoid carcinoma of the hypopha-
rynx. Regarding the epidemiological data presented, there 
is an agreement with the current literature in relation to 
male predominance and a higher prevalence in adults 
older than 45 years3. Currently, there is an increase in 
the incidence of this disease in women, although its 
behavior and prognosis are similar to cases involving 
men. Regarding age, its later presentation correlates with 
the long history of exposure to the major carcinogens 
- tobacco and alcohol, are also consistent with current 
epidemiological data5.
Figure 1. Disease-free survival in patients treated with surgery followed 
by radiotherapy.
Figure 2. Overall survival of the patients treated with surgery followed 
by radiotherapy.
in Figures 1 and 2, respectively. The mean two-year overall 
survival in this group was 47.5%, and 37.5% in five years.
Concomitant radiotherapy and chemotherapy was 
the initial treatment of choice in 40 patients (35%) and 
disease-free and overall survival and overall curves of this 
group were also traced following the Kaplan-Meier method 
and are depicted in Figures 3 and 4, respectively. Overall 
survival at two years was 40%, and 20% in five years.
Palliative chemotherapy was performed in three 
patients. Forty-five patients (39.4%) were untreated. Of 
this latter group, 18 died before the start of treatment or 
did not have medical conditions to withstand any form of 
therapy and 27 did not return after the first visit or after 
referral to radiotherapy.
Figure 3. Disease-free survival in the group treated with radiotherapy 
and chemotherapy.
Figure 4. Overall survival in the group treated with radiotherapy and 
chemotherapy.
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The prevalence of the initial symptoms and their 
distribution depict some anatomical and behavioral 
peculiarities of the disease because initial tumors can 
grow inside the piriform recess without causing signifi-
cant obstructive symptoms, thus leading patients to only 
show late symptoms of aerodigestive tract obstruction of 
the aerodigestive tract and pain arising from the neural 
infiltration2, as well as the patterns of submucosal spread 
of the lesions associated with the rich lymphatic network 
which cause early neck metastasis11, shown in the report 
results and identification of neck nodes as the first sign 
and most frequent symptom (28%).
Due to the large lymphatic spread and the silent 
character of the early cases previously reported, there is 
a high incidence of diagnosis of advanced clinical stages, 
showing, according to our data, 94.7% already in stages 
III and IV, contributing to the poor disease prognosis and 
survival.
Because of the high incidence of advanced cases, 
treatment is usually performed in combination - surgery 
followed by radiotherapy or radiotherapy and conco-
mitant chemotherapy. Regarding surgery, it may be a 
partial pharyngectomy, done in selected cases due to the 
intimate contact of that region with the larynx and the 
need for resection with oncologic margin encompassing 
this region, performed in our series in only one patient 
via pharyngotomy. The most commonly used approach is 
pharyngolaryngectomy with or without flap reconstruction 
of the digestive tract, depending on the involvement of 
the posterior wall of the hypopharynx and, lastly, pharyn-
golaryngoesophagectomy in cases of cervical esophagus 
involvement, requiring reconstruction with jejunum or 
making a gastric tube.
Neck dissection may complement the surgery, usu-
ally held together because of the high incidence of neck 
metastasis. Contralateral neck dissection is indicated in 
some patients, especially in cases of positive ipsilateral neck 
and lesions that cross the midline, they add a lower rate of 
regional recurrence without, however, significantly altering 
overall survival12. It is worth considering that, regardless of 
the treatment paradigm, better results were not detected.
In our series, surgery was used as initial therapy 
in 22.8% of cases, leading to a mean two-year survival of 
approximately 50% with stabilization and a new drop at 
five years - about 40%. Considering the generally poor 
nutritional status of these patients, other comorbidities 
they have, possible complications that a major surgery 
can produce in such circumstances coupled with the 
long recovery and rehabilitation process, and the low 
overall survival, we must consider each individual case 
when recommending such intervention, even though it is 
option with the best results in cancel control13 and be the 
treatment of choice in our clinic.
Radiotherapy was the initial treatment choice in 35% 
of the cases, always with chemotherapy that enhances 
the effect of the first treatment. In some of our patients, 
we used a neoadjuvant chemotherapy regimen, often 
with cisplatin and 5-fluorouracil - although not changing 
survival in some studies14, it may be predictive of res-
ponse to radiotherapy and chemotherapy. Even in the 
absence of partial response, it signals a poorer response 
to radiotherapy and quimioterapia15 and leads to modify 
the proposal for a surgical intervention. Regarding survival 
of this group, we have approximately 25% in two years 
and 20% in five years - a worse outcome when compared 
to the surgery group initially.
These results may stem from a selection bias, because 
as our protocol for advanced cases is surgery followed by 
radiation therapy and most patients already present with 
stages III and IV, we tend to refer to radiotherapy patients 
that have some criteria for tumor unresectability, such as 
invasion of the prevertebral fascia or major involvement of 
the internal carotid; or those who have comorbidities that 
contraindicate surgery, and other comorbidities such as 
malnutrition that often accompany these patients - which 
should not be an absolute contraindication to surgery16, but 
without proper support and multidisciplinary management 
it brings unacceptable risks to this procedure.
Considering some of the characteristics already 
mentioned inherent to patients and the tumor, three 
patients underwent palliative chemotherapy with no fur-
ther treatment and 45 patients went without treatment - a 
total of 39.4% of our sample, further corroborating the 
aggressiveness of the disease, and the multiplicity of factors 
involved in the decision to treat or not these patients and 
last treatment possibility that could be more effective and 
less harmful for this group.
Another important factor is the socio-economic level 
and family support of patients, mostly living in poverty 
and unable to maintain minimum hygiene, supportive care 
shown to depend on the treatment, as well as their com-
pliance towards it, and this another item to be considered 
in the management of these cases and also in impacting 
on the success of the treatment chosen17.
CONCLUSION
Considering the high mortality of this tumor, the 
frequency of advanced disease at initial presentation and 
major morbidity of both forms of treatment available, 
the therapeutic decision of the hypopharynx carcinoma 
remains a challenge. Due to the need for multifactorial 
evaluation of these patients, an individual analysis should 
be carried out and one should consider the experience of 
the surgical team, and the availability of resources so that 
the best therapeutic choice can be made for each case.
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